Enzymes, Signaling Proteins, Extracellular Ligands, Signaling Reagents, Antibodies
| Shopping Cart EN/中文
 

MUTANT KINASES - KIF5B-RET (Kex15Rex14), Active (R02-19FG)

Product Name Catalog Number Pack Size Price(USD)  
KIF5B-RET (Kex15Rex14), Active R02-19FG-05 5 ug $259 Add to Cart
KIF5B-RET (Kex15Rex14), Active R02-19FG-10 10 ug $380 Add to Cart
KIF5B-RET (Kex15Rex14), Active R02-19FG-BULK BULK Contact Us  


Description: Recombinant human fusion KIF5B (1- 575 a.a., exons1-15) –RET (713 a.a. – end, exons 14-21), was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Species: Human

Tag: GST tag

Expression System: Sf9 insect cells using baculovirus

Sequence: 1- 575 a.a., exons1-15 (KIF5B) – 713 a.a. – end, exons 14-21 (RET)

Genbank Number: NM_004521  NM_020630  


Specific Activity : Sample Activity Plot. For specific information on a given lot, see related technical data sheet.



Purity : Sample Purity Data. For specific information on a given lot, see related technical data sheet.



Storage, Stability, and Shipping : Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications : Kinase Assay

Molecular Weight : 132 kDa

Gene Aliases : KIF5B: KINH, UKHC, KNS
RET: CDHF12, RET51, PTC, RET-ELE1; RET/PTC2

Scientific Background : RET or ret proto-oncogene is a member of the cadherin superfamily that encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. RET can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement (1). RET signaling pathway, by regulating the development of both the nervous and lymphoid system in the gut, plays a key role in the molecular mechanisms that orchestrate intestine organogenesis (2). The KIF5B-RET fusion was reported to be one of the driver mutations of lung adenocarcinomas and that Vandetanib inhibits the anchorage-independent growth activity induced by the fusion.

References :
1. Grieco, M. et.al: PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60: 557-563, 1990.
2. Veiga-Fernandes, H. et.al: Tyrosine kinase receptors RET is a key regulator of Peyer's patch organogenesis. Nature 446: 547-551, 2007.
3. Kohno T, et al. : KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012 Feb 12;18(3):375-7.

Product Sheets

SDS

Research Areas
Cancer,

Related Products

  Terms of Service | Privacy Policy  
  @ 2018 SignalChem.All rights reserved